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Purpose: To evaluate the effectiveness of small interfering RNA 
(siRNA) targeting matrix metalloproteinase 9 (MMP-9) in 
suppressing granulation tissue formation caused by bare 
metallic stent placement in a rat urethral model.
Materials and 
Methods:
All experiments were approved by the committee of an-
imal research. In 20 Sprague-Dawley male rats (weight 
range, 300–350 g), a self-expanding metallic bare stent 
was inserted in the urethra with fluoroscopic guidance. 
One group of 10 rats (group A) was treated with MMP-9 
siRNA/bioreducible branched polyethylenimine–disulfide 
cross-linked–indocyanine green (bioreducible BPEI–SS-
ICG), while the other group of 10 rats (group B) received 
control siRNA/bioreducible BPEI–SS-ICG treatment. All 
rats were sacrificed at 4 weeks. The therapeutic effec-
tiveness of the MMP-9 siRNA/bioreducible BPEI–SS-ICG 
complex was assessed by comparing the two results of ret-
rograde urethrography, histologic examination, and quan-
tification of MMP-9 by using zymography and Western 
blot analysis between the two groups. The Mann-Whitney 
U test was used to evaluate differences.
Results: Stent placement was successful in all rats without a single 
case of migration at follow-up. Retrograde urethrogra-
phy performed 4 weeks after stent placement demon-
strated significantly larger luminal diameters of the ure-
thra within the stents in group A compared with those in 
group B (P = .011). Histologic analysis revealed that the 
mean percentage of granulation tissue area (P , .001), 
mean number of epithelial layers (P , .001), and mean 
thickness of submucosal fibrosis (P , .001) were signif-
icantly decreased in group A compared with group B. 
Meanwhile, the mean density of inflammatory cell infil-
tration did not significantly differ between the two groups 
(P = .184). Quantitative analysis disclosed MMP-9 levels 
to be lower in group A relative to group B, indicating pos-
itive inhibition of MMP-9 by MMP-9 siRNA/bioreducible 
BPEI–SS-ICG.
Conclusion: MMP-9 siRNA/bioreducible BPEI–SS-ICG is effective for 
inhibiting granulation tissue formation after bare metallic 
stent placement in a rat urethral model.
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water (molecular weight cutoff, 8000) 
and lyophilized.
Indocyanine green (ICG) is a fluo-
rescent dye, and it is deemed suitable 
in in vivo studies, as it emits near-in-
frared fluorescence, and unlike nor-
mal fluorescence, it provides deep 
tissue penetration. ICG dye was conju-
gated to bioreducible BPEI–SS accord-
ing to the reported method with some 
modifications (8). Triethylamine and 
6-aminohexanoic acid were added to a 
solution of ICG in anhydrous dimethyl-
formamide and stirred for 5 hours at 
85°C. The product was purified with 
column chromatography by using ethyl-
acetate and methanol as eluent (AcOEt/
MeOH, 70/30–0/100) to afford the com-
pound as a blue solid (ICG−COOH). To 
synthesize bioreducible BPEI–SS-ICG, 
N-(3-dimethylaminoproply)-N’-ethylcar-
bodiimide hydrochloride) was added to 
the ICG−COOH in anhydrous dimethyl-
formamide at room temperature. Then, 
a solution of bioreducible BPEI–SS in 
dimethylformamide was added, and the 
reaction mixture was stirred at room tem-
perature for 24 hours. The product was 
purified by means of repeated ultrafiltra-
tion against methanol and water (molec-
ular weight cutoff, 10 000) twice, followed 
by lyophilization. The degree of ICG con-
jugation with bioreducible BPEI–SS was 
and Use Committee of Asan Medical 
Center (Seoul, Korea).
Animals
Our study was carried out by using rat 
models composed of 20 male Sprague-
Dawley rats weighing 300–350 g at 9 
weeks of age. Rats were maintained on a 
diet of rodent feed and water ad libitum 
at 24°C 6 1, 55% 6 10 humidity, and 
a 12 hour day-night cycle under specific 
pathogen-free conditions. Animals were 
acclimatized for at least 7 days prior to 
the start of the experiments.
Synthesis of Bioreducible Branched 
Polyethylenimine–Disulfide Cross-linked–
Indocyanine Green
The branched polyethylenimine (BPEI)−
sulfhydryl (SH) (thiolated BPEI) was 
synthesized by employing the previously 
reported method with some modifica-
tions (7). Briefly, the pH of BPEI 1.2-
kDa (molecular weight of BPEI) solu-
tion was adjusted to 7.2 by adding 1N 
(normal concentration of ionic solution) 
HCl. Then, the solution was lyophilized 
by means of freeze-drying for 2 days 
to afford BPEI as a yellow solid, which 
was then dissolved in methanol, and the 
resultant solution was purged with ni-
trogen. After adding propylene sulfide 
(7 equivalent) through a syringe, the 
reaction mixture was stirred at 60°C 
for 24 hours. The product was obtained 
by precipitating in cold ether twice, and 
the degree of thiolation was measured 
with proton nuclear magnetic reso-
nance spectroscopy. For the synthesis 
of bioreducible BPEI–disulfide cross-
linked (SS), BPEI−SH was dissolved in 
dimethyl sulfoxide, and oxidative cross-
linking was performed by stirring the 
solution at room temperature for 48 
hours. Finally, the product was puri-
fied by using dialysis against deionized 
Different types of expandable me-tallic stents, including bare or covered stents, have been used 
in the treatment of benign or malignant 
strictures involving nonvascular luminal 
organs. However, even after successful 
stent placement, subsequent formation 
of granulation tissue within the stent 
lumen remains a major problem and 
has been the center of attention, giving 
birth to various ongoing investigations 
to preserve stent patency (1–5). There-
fore, it is essential to understand the 
pathophysiologic process of granulation 
tissue formation to develop ways to sup-
press it.
Recent research has disclosed nu-
merous mediators involved in various 
steps of granulation tissue formation. 
Among many cytokines and growth fac-
tors that are involved in the prolifera-
tion of granulation tissue, matrix me-
talloproteinase 9 (MMP-9) is known to 
play a central role in the proliferation 
of fibrosis (6).
We hypothesized that, by target-
ing MMP-9, it is possible to prevent 
formation of granulation tissue after 
stent placement. In our study, we ad-
vocated an RNA interference (RNAi) 
technique, a sequence-specific gene 
silencing process, to target MMP-9 by 
using small interfering RNA (siRNA). 
RNAi is a mechanism of gene expres-
sion downregulation that is dependent 
on the target nucleotide sequence. The 
purpose of our study was to evaluate 
the effectiveness of siRNA targeting 
MMP-9 in suppressing granulation tis-
sue formation caused by bare metallic 
stent placement in a rat urethral model.
Materials and Methods
All experimental procedures were ap-
proved by the institutional Animal Care 
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approach for preventing stent-
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 n Direct and local treatment with 
small interfering RNA (siRNA) 
targeting matrix metalloprotein-
ase 9 (MMP-9) was effective in 
preventing tissue hyperplasia sec-
ondary to stent placement in a 
rat urethral model.
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Xenogen), according to the manufac-
turer’s instructions.
Urethrographic Examination
Fluoroscopically guided (Artis Zee Mul-
tipurpose; Siemens, Muenchen, Ger-
many) retrograde urethrography was 
performed in right anterior oblique 
projections with use of a calibrated 
catheter, with anesthesia, in all rats 
immediately after stent placement to 
verify position of the stent and passage 
of contrast medium (Omnipaque 300; 
GE Healthcare, Cork, Ireland). This 
procedure was repeated 4 weeks later 
to assess changes in diameter within 
the stent. Luminal diameter was mea-
sured on urethrograms, and a calibrat-
ed catheter, which was constructed in 
our research laboratory, was used for 
reference. A software package (Photo-
shop, version 6.0; Adobe Systems, Palo 
Alto, Calif) was used to acquire digital 
measurements of the inner luminal di-
ameter of the segment with the stent 
at three different levels. Measurements 
were repeated three times at each level, 
yielding the average value per level, and 
these values were subsequently aver-
aged to obtain an overall average diam-
eter of the segment of the urethra with 
the stent. Urethral stenosis secondary 
to granulation tissue formation within 
the stents was graded according to se-
verity with reference to a previous ar-
ticle (9), as follows: grade 0, normal; 
grade 1, mild urethral wall irregularity; 
grade 2, filling defect of less than one-
half of the stent diameter; and grade 3, 
filling defect of more than one-half of 
the stent diameter. Grading of urethral 
group, group A (treatment group), was 
treated with MMP-9 siRNA/bioreduc-
ible BPEI–SS-ICG complex after place-
ment of the urethral stent, while the 
second group, group B (control group), 
received control siRNA/bioreduc-
ible BPEI–SS-ICG complex treatment 
following stent placement (E.Y.K. and 
J.H.P., with more than 5 years of ex-
perience in interventional radiology). 
In both groups, siRNA/bioreducible 
BPEI–SS-ICG complex was adminis-
tered retrograde via the urethral open-
ing on a weekly basis for 3 weeks. To 
retain the treatment complex within 
the urethra, its spillage into the blad-
der was prevented by clamping the 
bladder neck with a clamp (Jeungdo 
Bio & Plant, Seoul, Korea). This was 
achieved by performing an open mid-
line incision in the lower abdominal 
wall, with the animal anesthetized, and 
partially extracting the bladder for ac-
curate visualization and placement of 
the device. For the same purpose, a 
second clamp was applied to the pe-
nile urethra to obstruct outflow. Both 
clamps were maintained for 30 minutes 
before they were removed. Repair of 
the abdominal wall was performed 
thereafter. The rats were maintained in 
a temperature-controlled room (24°C) 
and supplied with autoclaved food and 
water during the recovery period. On 
the 4th week, all rats in group A and 
group B were sacrificed to evaluate the 
degree of stent-induced tissue hyper-
plasia in each group.
The properties of the capability 
of bioreducible BPEI–SS-ICG to de-
liver MMP-9 siRNA or control siRNA 
in vivo were assessed in all rats after 
1 minute and 30 minutes after injec-
tion of the MMP-9 siRNA/bioreduc-
ible BPEI–SS-ICG or control siRNA/
bioreducible BPEI–SS-ICG by using an 
imaging system (Vivo Vision Systems, 
IVIS 200 Series Imaging System; Xe-
nogen, Alameda, Calif). ICG absorbed 
mainly between 600 nm and 900 nm 
and emitted fluorescence between 750 
nm and 950 nm. During imaging, rats 
were anesthetized with 2.5% isoflurane 
gas in the oxygen flow (1.5 L/min). 
Images were analyzed by using soft-
ware (Living Image 2.50-Igor Pro 4.09; 
estimated by using the ultraviolet and 
visible spectrometry method. Bioreduc-
ible BPEI–SS-ICG can form nano-sized 
complex (polyplex) with siRNA by means 
of electrostatic interaction. Once poly-
plex gets internalized into the cell, it can 
escape from the endosome through the 
proton-sponge effect. Furthermore, due 
to the reducing environment of cytosolic 
compartments, the disulfide bond can be 
reduced and cleaved to the thiol group. 
As a result, cross-linked bioreducible 
BPEI can be degraded to low–molecular-
weight BPEI.
Preparation of siRNA/bioreducible BPEI–
SS-ICG
siRNA targeting rat MMP-9 and control 
siRNA (nonspecific siRNA) were pur-
chased from a commercial supplier (Qia-
gen Technologies, Coralville, Iowa). The 
MMP-9–silencing effect of siRNAs was 
determined by using gelatin zymography 
and Western blot analysis. Complexes 
were formed by gently mixing siRNA 
with bioreducible BPEI–SS-ICG (in 5% 
glucose) solutions. The siRNA/bioreduc-
ible BPEI–SS-ICG complex formation 
was confirmed by polyacrylamide gel re-
tardation assays. The bioreducible BPEI–
SS-ICG and the siRNA dose of 60 mmol/L 
complex (30:1 nitrogen-phosphorus ra-
tios) were used in the animal study.
Stent Construction and Placement
The self-expandable metallic bare 
stent was woven from a single thread 
of nitinol wire filament of 0.1 mm in 
thickness (Taewoong, Kimpo, Gyunggi, 
Korea). Its diameter and length were 
3 mm and 8 mm, respectively, at full 
expansion. The stent size was chosen 
considering the diameter (2.8 mm) and 
length (15 mm) of the normal urethra 
in rats weighing 300–350 g at 9 weeks 
of age (9). It possessed six bend points 
on each end with radiopaque markers 
on either end to aid accurate deploy-
ment within the urethra (Fig 1).
Details in regard to the stent place-
ment technique have been described by 
researchers in previous studies (9).
Techniques in Complex Treatment
The rats were randomized and divided 
into two groups of 10, where the first 
Figure 1
Figure 1: Self-expanding bare metallic stent. 
When fully expanded, the stent is 3 mm in diameter 
and 8 mm in length. Gold markers were attached to 
either end of the stent.
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resolved with 10% sodium dodecylsul-
fate–polyacrylamide gel electrophore-
sis. Gels containing proteins were trans-
ferred to the nitrocellulose membranes, 
and the membranes were blocked with 
5% nonfat skim milk dissolved in Tris 
buffer saline containing 0.1% Tween 
20 (Sigma Chemical) for 1 hour. After 
membrane washing with Tris buffer 
saline containing 0.1% Tween 20 for 
three times, membranes were incu-
bated in primary antibodies diluted in 
Tris-buffered saline containing 0.1% 
Tween 20 at 4°C overnight with gen-
tle agitation and again the membranes 
were washed. Then, they were incu-
bated in secondary antibodies conju-
gated to horseradish peroxidase. The 
target proteins were detected by using 
reagents (ECL Western Blotting Detec-
tion Reagents; Amersham Biosciences, 
Little Chalfont, Buckinghamshire, Eng-
land). Targets were MMP-9 primary 
antibodies (Abcam, Cambridge, Mass) 
and b-actin primary antibodies (Sigma 
Chemical).
Statistical Analysis
Differences between animal groups 
with respect to the degree of urethral 
narrowing demonstrated at retrograde 
urethrography, percentage of granu-
lation tissue formation, values for the 
number of epithelial layers, thickness 
of submucosal fibrosis, and the extent 
of inflammation demonstrated on mi-
croscopic images were tested by using 
the Mann-Whitney U test. A P value of 
less than .05 was considered to indi-
cate a significant difference. Statistical 
software (SPSS, version 19.0; SPSS, 
Chicago, Ill) was used to perform the 
analyses.
Results
Stent Placement
Stent placement was technically suc-
cessful, without difficulty, in all rats. A 
small amount of hematuria occurred 
immediately after stent placement in 
all rats, but it spontaneously subsided. 
During stent placement in two rats in 
group B, the stent introducer was re-
sponsible for urethral perforation. 
using software (Image-Pro Plus; Media 
Cybernetics, Silver Spring, Md).
Quantitative Analysis for MMP-9
MMP-9 in the rat urethral tissue was 
quantified by means of zymography and 
Western blot analysis. For quantifica-
tion of MMP-9, the tissue was snap-
frozen in liquid nitrogen and stored at 
2196°C in a nitrogen tank until extrac-
tion of protein.
Gelatin zymography.—The samples 
were prepared with homogenization 
of the tissues in the lysis buffer (Cell 
Signaling Technology, Beverly, Mass). 
The homogenates were centrifuged at 
10 000g for 15 minutes at 4°C, and 
the supernatants were collected for 
analysis. Tissue extracts were analyzed 
by using 10% sodium dodecylsulfate–
polyacrylamide gel electrophoresis 
(SDS-PAGE; Invitrogen, Grand Island, 
NY) with 0.1% gelatin incorporated as 
a substrate for gelatinolytic proteases 
with nonreducing conditions at 125 V 
for 90 minutes. Equal amounts of tis-
sue extract protein (20 µg), determined 
by using the method of Bradford (11), 
were loaded onto the gels. After elec-
trophoresis, the gels were incubated 
twice in renaturing buffer (2.5% Tri-
tonX-100; Sigma Chemical, St Louis, 
Mo) for 30 minutes at room temper-
ature, with gentle agitation to remove 
sodium dodecylsulfate. The gels were 
equilibrated once for 30 minutes at 
room temperature in developing buffer 
(50 mmol/L tris[hydroxymethyl]amino-
methane [Tris; Sigma Chemical] base, 
50 mmol/L Tris HCl [Sigma Chemi-
cal], 0.2 mol/L NaCl, 5 mmol/L CaCl2, 
0.02% Brij 35 [Sigma Chemical]), and 
then the membranes were incubated 
at 37°C overnight in fresh developing 
buffer to activate metalloproteinases. 
The gels were stained with 0.5% Coo-
massie brilliant blue R-250 (Bio-Rad, 
Hercules, Calif) for 2 hours and de-
stained in a destaining solution of meth-
anol, acetic acid, and distilled water 
in a ratio of 4.5:1:4.5. The molecular 
weight of each band was estimated by 
comparison with the positions of known 
molecular-weight standards (Bio-Rad).
Western blot analysis.—Equal 
amounts of protein (30 µg) were 
stenosis was performed by three ob-
servers (J.H.K, E.Y.K., and J.H.P, with 
more than 5 years of experience in in-
terventional radiology) in consensus.
Histologic Examination
All rats were sacrificed by means of 
administration of inhalable pure car-
bon dioxide. Surgical exploration of 
the urethra and urinary bladder were 
performed. The urethral tissue samples 
were fixed in 10% neutral buffered for-
malin for 24 hours. Fixed tissue sam-
ples were then sectioned transversely 
at the proximal, middle, and distal 
portions of the segment with the stent. 
Cut stent wires were removed from 
the specimens, and care was taken to 
preserve the hyperplastic tissue area. 
The specimens were then processed 
for microscopic examination. Histo-
logic evaluation was performed with a 
microscope to determine the percent-
age of granulation tissue–related ste-
nosis calculated with 100 · (12 [Lsten/
Lorig]), where Lsten is stenotic lumen 
cross-sectional area and Lorig is original 
lumen cross-sectional area. The degree 
of submucosal inflammatory cell infil-
tration (macrophage, monocyte, lym-
phocyte) was subjectively determined 
according to the distribution and den-
sity of the inflammatory cells (grade 
1, mild; grade 2, mild to moderate; 
grade 3, moderate; grade 4, moderate 
to severe; and grade 5, severe) (10). 
The average values for the number of 
epithelial layers and thickness of sub-
mucosal fibrosis were obtained from 
averaging eight points (including max-
imum and minimum points) around the 
circumference. One pathologist (J.Y.R., 
with 30 years of experience in genito-
urinary pathology) carried out urethral 
diameter measurements at three differ-
ent levels for each animal in a manner 
similar to that described above for di-
ameter measurements on retrograde 
urethrograms. The average value per 
level and overall average diameter were 
yielded through this process. Histologic 
analysis of the urethra was performed 
with a microscope (BX51; Olympus, 
Tokyo, Japan) equipped with magnifi-
cation capabilities of ×1.25, ×20, and 
×40. Measurements were obtained by 
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the remaining three rats. In group B, 
granulation grades were determined to 
be grade 1 in two rats, grade 2 in three 
rats, and grade 3 in the remaining five 
rats.
Histologic Results
The histologic findings are summarized 
in Table 2, and an example is shown in 
Figure 4. Granulation tissue formation 
was seen in both groups, but in corre-
lation with the findings at retrograde 
urethrography, the mean percentage 
of granulation tissue area was lower 
for group A compared with group B 
(62.38 6 11.20 vs 70.22 6 7.17, P = 
.011), indicating effective suppression 
of stent-induced tissue hyperplasia with 
MMP-9 siRNA/bioreducible BPEI–SS-
ICG. Furthermore, the mean number 
of epithelial layers and mean thickness 
of submucosal fibrosis in millimeters 
were significantly decreased in group A 
relative to group B, with 3.42 6 0.78 
BPEI–SS-ICG or control siRNA/biore-
ducible BPEI–SS-ICG.
Urethrographic Results
The average luminal diameter of the 
urethra within the proximal, middle, 
and distal segments of the stent and 
average overall luminal diameter at 
follow-up retrograde urethrography 
for groups A and B are summarized in 
Table 1. In group A, the mean luminal 
diameter of the three segments at fol-
low-up retrograde urethrography was 
significantly larger compared with that 
in group B at 4 weeks after stent place-
ment (2.32 6 0.45 vs 1.78 6 0.31, P 
, .001) (Fig 3). When data from the 
two rats with urethral perforation were 
omitted, these results retained signifi-
cance (mean, 2.32 6 0.45 vs 1.86 6 
0.38; P , .001). The grades of granula-
tion tissue formation after stent place-
ment in group A were determined to 
be grade 1 in seven rats and grade 2 in 
However, spontaneous healing of ure-
thral perforation was demonstrated at 
retrograde urethrography performed 4 
weeks after the event. All rats survived 
until the end of the study without a sin-
gle case of stent migration.
Optical Imaging in Vivo
Figure 2 shows the optical images of a 
rat before (Fig 2, A) and after 1 mi-
nute (Fig 2, B) and 30 minutes from 
the injection of MMP-9 siRNA/biore-
ducible BPEI–SS-ICG (Fig 2, C). Fig-
ure 2, D, shows the three-dimensional 
reconstruction of the rat body and the 
organs of interest. Also, in this case, af-
ter the injection of the MMP-9 siRNA/
bioreducible BPEI–SS-ICG, optical im-
ages showed signal intensity enhance-
ment in the region corresponding to 
the urethra. All rats in both groups 
showed positive signal intensity en-
hancement after 30 minutes from the 
injection of MMP-9 siRNA/bioreducible 
Figure 2
Figure 2: In vivo imaging in a rat with 2 mg/mL penis injection of MMP-9 siRNA/bioreducible BPEI–SS-ICG. A, Before injection. B, 
At 1 minute after injection. C, At 30 minutes after injection. D, Image is a three-dimensional reconstruction of rat body and organs of 
interest. Color bar = signal efficiency of the fluorescence emission coming out from the animal.
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various obstructive conditions of the 
hollow viscera. The gastrointestinal and 
biliary tracts, which are susceptible to 
both benign and malignant strictures, 
have largely benefited from such de-
velopments. With recent achievements 
with respect to technical success in 
stent placement, attention has now 
turned to long-term preservation of 
stent patency (3,12–15). This direction 
has resulted in new ideas to preserve 
stent patency, leading to the develop-
ment of covered stents and drug-eluting 
stents among others (4,16–19). While 
the former creates a physical barrier to 
hinder ingrowth of benign tissue hyper-
plasia and malignant tissue, the latter 
focuses on prevention of their growth. 
With regard to prevention of benign tis-
sue hyperplasia that is often a cause of 
stent obstruction induced by the stent 
itself, various substances, such as the 
ALK-5 inhibitor 3-{[4-(6-methylpyri-
din-2-yl)-5-(quinolin-6-yl)-1H-imidazol-
2-yl] methyl} benzamide (IN-1233), 
dexamethasone, paclitaxel, and pro-
teinase inhibitors, have been applied in 
vitro and in vivo in an effort to discover 
one that provides optimal suppres-
sion of granulation tissue formation 
(9,10,14,15,19–23). As past research 
has shown, granulation tissue is a re-
sult of tissue remodeling, which itself is 
a complex multistep process involving a 
variety of mediators.
Matrix metalloproteinases, a fam-
ily of zinc-dependent proteinases with 
extracellular matrix remodeling and 
degrading properties, are among those 
that have been demonstrated to play a 
key role in the process of tissue remod-
eling (6,24,25). MMP-9 is one of the 
two matrix metalloproteinases that has 
been found to be highly expressed dur-
ing the process of vascular remodeling 
and tumor growth. Along the same line, 
Shin et al (15) reported that expression 
of MMP-9 was significantly increased in 
tracheal granulation tissue formation 
induced by stent placement relative to 
levels found in normal tissue in a rat 
tracheal model. On the basis of these 
results, inhibition of tissue hyperplasia 
by targeting MMP-9 could potentially 
halt the process of stent-induced tis-
sue growth. Matrix metalloproteinase 
(92 kDa). The 10% sodium dodecylsul-
fate–polyacrylamide gel electrophoresis 
zymography and Western blot analyses 
revealed that MMP-9 expression was 
more substantially inhibited in group A 
than in group B (Figs 5, 6). These re-
sults indicated effective gene silencing 
with siRNA targeting MMP-9.
Discussion
Recent advances in stent technology 
have greatly contributed to increased 
success rates in stent placement in 
versus 5.90 6 1.01 (P , .001) and 0.75 
6 0.17 versus 1.48 6 0.39 (P , .001), 
respectively. The mean density grade 
of inflammatory cell infiltration did not 
differ among the two groups, with 2.50 
6 0.72 versus 2.71 6 0.81 (P = .184). 
When data from the two rats with 
urethral perforation were omitted, 
these results also retained significance 
(Table 3).
Quantitative Analysis for MMP-9
The identities of the lytic zones on the 
gelatin zymograms represented MMP-9 
Table 1
Urethrographic Findings after Stent Placement
Location Group A (n = 10) Group B (n = 10) Group B (n = 8)*
P Value, Group A  
Versus B
P Value, Group A  
Versus B*
Proximal 2.48 6 0.42 1.79 6 0.18 1.83 6 0.16 ,.001 ,.001
Middle 2.27 6 0.45 1.78 6 0.23 1.84 6 0.22 .01 .024
Distal 2.22 6 0.48 1.78 6 0.47 1.89 6 0.48 .063 .181
Average 2.32 6 0.45 1.78 6 0.31 1.86 6 0.38 ,.001 ,.001
Note.—Data are mean diameters of the area with a stent in millimeters 6 standard deviations except where otherwise 
indicated; diameters and P values were determined at 4 weeks after stent placement.
* For group B, data from two rats with urethral perforation were omitted.
Figure 3
Figure 3: Retrograde urethrogram performed 4 weeks following stent placement in, A, group A animal 
(treatment group) and, B, group B animal (control group) demonstrates a larger luminal diameter (arrows) in 
group A animal relative to group B animal owing to suppressed stent-induced tissue hyperplasia with MMP-9 
siRNA/bioreducible BPEI–SS-ICG.
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Figure 4
Figure 4: Histologic specimens of, A, group A animal (treatment group) and, B, group B animal (control 
group) revealed granulation tissue formation in both groups, but the average area of granulation tissue was 
lower for group A relative to group B, indicating effective suppression of stent-induced tissue hyperplasia 
with MMP-9 siRNA/bioreducible BPEI–SS-ICG. (Hematoxylin-eosin; original magnification, ×1.25.)
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inhibitors that have been developed and 
applied in medicine include GM6001, 
TIMP, and doxycycline, all of which 
have demonstrated therapeutic effect 
to some extent (26–28). However, con-
cerns about their safety, such as drug 
toxicity and nonspecific effects, have 
hindered their widespread use.
In our study, we advocated the 
RNAi technique by using bioreduc-
ible BPEI–SS-ICG–delivered siRNA to 
suppress granulation tissue formation 
within the stent lumen. Ever since its 
introduction 10 years ago, the phenom-
enon of RNAi has drawn widespread 
attention of researchers from all over 
the world (29). It is an RNA-dependent 
gene-silencing process controlled by 
the RNA-induced silencing complex, 
or RISC, that moderates the activity of 
genes in living organisms. Theoretically, 
RNAi can be exploited in therapeutic 
medicine by introducing siRNA into 
specific target genes. However, previous 
attempts at delivery of siRNA into cells 
for gene silencing have gone through 
trials and errors owing to the lack of ef-
ficient delivery systems. Stability of the 
siRNA after its administration into the 
body and efficient cellular uptake and 
transfection are key steps to the suc-
cessful delivery of siRNA into the target 
tissue. In this light, the selection of an 
appropriate delivery system (vector) is 
mandatory, and, recently, a majority of 
proposed clinical applications of RNAi 
use siRNA duplexes, delivered into cells 
by nonviral vectors. Among numerous 
nonviral vectors that have been applied, 
bioreducible BPEI is regarded as one of 
the most effective nonviral vectors (30). 
In the current study, we chose biore-
ducible BPEI–SS-ICG for the delivery 
system of siRNA to target MMP-9. Even 
with difficulties that lie in its applica-
tion, RNAi offers an alternative access 
to disease therapy where it prevents 
the expression of disease-associated 
proteins at the RNA level, in contrast to 
most drugs that act at the protein level.
At comparison of the results of 
retrograde urethrography between 
group A and group B, the luminal di-
ameter of the urethra with a stent was 
larger for the former, indicating effec-
tive suppression of tissue hyperplasia 
following stent insertion. To support 
the gross findings at urethrography, 
histologic examination of the urethra 
was performed to reveal a lower area of 
granulation tissue in group A, thereby 
positively correlating with the urethro-
graphic results. In our study, urethral 
perforation caused by the stent intro-
ducer during stent placement occurred 
in two rats in group B. However, when 
data from the two rats with urethral 
perforation were omitted, significant 
results were retained. In the study by 
Shin et al (15), zymography and West-
ern blot analysis targeting MMP-9 dem-
onstrated overexpressed MMP-9 in the 
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Figure 5
Figure 5:  The 10% sodium dodecylsulfate–polyacrylamide gel electrophoresis zymography revealed that 
MMP-9 expression was inhibited in, A, group A relative to, B, group B, indicating effective gene silencing with 
siRNA targeting MMP-9.
Figure 6
Figure 6: Western blot analysis revealed that MMP-9 expression was inhibited in, A, group A relative to, B, 
group B, indicating effective gene silencing with siRNA targeting MMP-9.
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stent-induced granulation tissue forma-
tion but not in the normal tissue in a 
rat tracheal model. They suggested that 
MMP-9 may be a key prognostic fac-
tor in stent-induced granulation tissue 
formation and that tailored treatment 
targeting MMP-9 could be promising 
to control granulation tissue formation. 
The findings in the present study are in 
line with theirs in which its intent was 
to suppress MMP-9 by using the RNAi 
technique. The results acquired from 
this study were positive where MMP-9 
siRNA successfully inhibited MMP-9 ex-
pression, not only shown by suppressed 
tissue growth within the stents but also 
demonstrated at quantitative analysis of 
MMP-9 with zymography and Western 
blot analyses.
There were a few limitations to our 
study. The first limitation lies in the 
dose of MMP-9 siRNA/bioreducible 
BPEI–SS-ICG and treatment schedule. 
Only a single fixed dose was given to 
each rat, yielding the results in our 
study. However, the optimal dose for 
suppressing tissue hyperplasia is not 
known, and we cannot exclude the 
possibility that the results would be 
affected by treatment dose. Second, 
although we chose to use rats treated 
with control siRNA/bioreducible BPEI–
SS-ICG as the animal model control, 
the strength of the results may be en-
hanced by using MMP-9 knockout ani-
mals instead. According to the theory 
on which our study is based, tissue 
hyperplasia would neither be induced 
nor suppressed in MMP-9 knockout an-
imals. Third, results of MMP-9 siRNA/
bioreducible BPEI–SS-ICG withdrawal 
were not obtained. If it had been shown 
that tissue hyperplasia was reinduced 
after withdrawal of treatment, it would 
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have provided further evidence to sup-
port the effectiveness of MMP-9 siRNA/
bioreducible BPEI–SS-ICG in inhibit-
ing stent-induced tissue hyperplasia. 
Fourth, the side effects of MMP-9-tar-
geting siRNA were not evaluated in our 
study. Given that nonspecific effects of 
RNAi treatment drugs are huge draw-
backs to their application in medicine, 
further research should be undertaken 
to clarify the issue.
In conclusion, MMP-9 siRNA/bio-
reducible BPEI–SS-ICG is effective for 
inhibiting granulation tissue formation 
after bare metallic stent placement in a 
rat urethral model.
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